PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2

Attached files

file	filename
8-K - PDL BIOPHARMA, INC.	v213742_8k.htm
EX-99.1 - PDL BIOPHARMA, INC.	v213742_ex99-1.htm

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1		Q2		Q3		Q4		Total
2011		22,208		-		-		-		22,208
2010		16,870		44,765		29,989		24,922		116,547
2009		13,605		35,161		21,060		15,141		84,966
2008		9,957		30,480		19,574		12,394		72,405
2007		8,990		21,842		17,478		9,549		57,859
2006		10,438		15,572		15,405		12,536		53,952

Herceptin	Q1		Q2		Q3		Q4		Total
2011		25,164		-		-		-		25,164
2010		23,402		38,555		27,952		25,441		115,350
2009		16,003		32,331		26,830		18,615		93,779
2008		14,092		34,383		28,122		20,282		96,880
2007		19,035		28,188		22,582		14,802		84,608
2006		15,142		19,716		21,557		20,354		76,769

Lucentis	Q1		Q2		Q3		Q4		Total
2011		8,878		-		-		-		8,878
2010		7,220		19,091		10,841		8,047		45,198
2009		4,621		12,863		8,123		6,152		31,759
2008		3,636		11,060		7,631		4,549		26,876
2007		2,931		6,543		6,579		3,517		19,570
2006		-		-		289		3,335		3,624

Xolair	Q1		Q2		Q3		Q4		Total
2011		4,590		-		-		-		4,590
2010		3,723		6,386		4,980		4,652		19,741
2009		2,665		5,082		4,085		3,722		15,553
2008		1,488		4,866		3,569		2,927		12,850
2007		1,684		3,942		3,332		2,184		11,142
2006		2,263		2,969		3,041		2,495		10,768

Tysabri	Q1		Q2		Q3		Q4		Total
2011		9,891		-		-		-		9,891
2010		8,791		8,788		8,735		9,440		35,754
2009		6,656		7,050		7,642		8,564		29,912
2008		3,883		5,042		5,949		6,992		21,866
2007		839		1,611		2,084		2,836		7,370
2006		-		-		-		237		237

Actemra	Q1		Q2		Q3		Q4		Total
2011		913		-		-		-		913
2010		1,587		237		315		688		2,827
2009		585		537		909		1,197		3,228
2008		44		116		179		369		708
2007		32		326		32		34		425
2006		-		-		-		-		-

* As reported to PDL by its licensees

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin	Q1		Q2		Q3		Q4		Total
2011		1,597,461		-		-		-		1,597,461
2010		1,586,093		1,596,892		1,594,707		1,646,218		6,423,910
2009		1,345,487		1,295,536		1,439,730		1,514,053		5,594,806
2008		980,715		1,084,930		1,180,427		1,239,382		4,485,454
2007		678,068		746,587		797,013		875,084		3,096,752
2006		439,318		516,052		570,551		592,897		2,118,817

Herceptin	Q1		Q2		Q3		Q4		Total
2011		1,391,568		-		-		-		1,391,568
2010		1,337,732		1,349,512		1,300,934		1,409,310		5,397,488
2009		1,210,268		1,133,993		1,226,435		1,278,626		4,849,323
2008		1,105,426		1,195,215		1,211,982		1,186,806		4,699,428
2007		891,761		949,556		979,602		1,015,033		3,835,952
2006		529,585		659,719		761,099		803,576		2,753,979

Lucentis	Q1		Q2		Q3		Q4		Total
2011		887,757		-		-		-		887,757
2010		759,965		698,890		745,376		804,684		3,008,915
2009		462,103		469,736		555,296		615,212		2,102,347
2008		363,615		393,682		460,167		454,922		1,672,386
2007		224,820		219,579		299,995		322,300		1,066,695
2006		-		-		10,689		157,742		168,431

Xolair	Q1		Q2		Q3		Q4		Total
2011		267,754		-		-		-		267,754
2010		240,904		225,878		251,055		263,389		981,225
2009		184,669		181,086		211,006		219,693		796,454
2008		137,875		169,521		177,179		183,753		668,329
2007		129,172		130,700		144,250		147,754		551,876
2006		95,241		99,354		112,608		118,002		425,204

Tysabri	Q1		Q2		Q3		Q4		Total
2011		329,696		-		-		-		329,696
2010		293,047		287,925		293,664		316,657		1,191,292
2009		221,854		229,993		257,240		285,481		994,569
2008		129,430		163,076		200,783		233,070		726,359
2007		30,468		48,715		71,972		94,521		245,675
2006		-		-		-		7,890		7,890

Actemra	Q1		Q2		Q3		Q4		Total
2011		30,433		-		-		-		30,433
2010		52,908		5,405		10,493		22,919		91,725
2009		19,504		17,920		30,313		39,888		107,627
2008		1,452		1,377		5,981		12,305		21,116
2007		2,388		873		1,071		1,137		5,470
2006		-		-		-		-		-

* As reported to PDL by its licensees

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3			2010 - Q4			2011 - Q1
US Made & Sold		795,199			795,453			814,872			820,453			800,139			708,539
US Made & ex-US Sold		718,855			703,661			355,742			338,929			415,576			580,981
ex-US Made & Sold		-			86,979			426,277			435,325			430,503			307,941
Total		1,514,053			1,586,093			1,596,892			1,594,707			1,646,218			1,597,461
US Made & Sold		53	%		50	%		51	%		51	%		49	%		44	%
US Made & ex-US Sold		47	%		44	%		22	%		21	%		25	%		36	%
ex-US Made & Sold		0	%		5	%		27	%		27	%		26	%		19	%

Herceptin Sales	2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3			2010 - Q4			2011 - Q1
US Made & Sold		386,654			394,883			406,222			410,563			416,611			409,854
US Made & ex-US Sold		608,046			372,146			312,792			306,085			425,303			423,053
ex-US Made & Sold		283,926			570,703			630,498			584,286			567,396			558,661
Total		1,278,626			1,337,732			1,349,512			1,300,934			1,409,310			1,391,568
US Made & Sold		30	%		30	%		30	%		32	%		30	%		29	%
US Made & ex-US Sold		48	%		28	%		23	%		24	%		30	%		30	%
ex-US Made & Sold		22	%		43	%		47	%		45	%		40	%		40	%

Lucentis Sales	2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3			2010 - Q4			2011 - Q1
US Made & Sold		266,405			323,153			300,501			326,840			360,911			378,451
US Made & ex-US Sold		348,808			436,812			398,389			418,536			443,773			509,307
ex-US Made & Sold		-			-			-			-			-			-
Total		615,212			759,965			698,890			745,376			804,684			887,757
US Made & Sold		43	%		43	%		43	%		44	%		45	%		43	%
US Made & ex-US Sold		57	%		57	%		57	%		56	%		55	%		57	%
ex-US Made & Sold		0	%		0	%		0	%		0	%		0	%		0	%

Xolair Sales	2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3			2010 - Q4			2011 - Q1
US Made & Sold		150,950			157,503			145,245			165,109			170,001			164,621
US Made & ex-US Sold		10			-			-			-			-			-
ex-US Made & Sold		68,733			83,401			80,632			85,945			93,388			103,133
Total		219,693			240,904			225,878			251,055			263,389			267,754
US Made & Sold		69	%		65	%		64	%		66	%		65	%		61	%
US Made & ex-US Sold		0	%		0	%		0	%		0	%		0	%		0	%
ex-US Made & Sold		31	%		35	%		36	%		34	%		35	%		39	%

Total Sales	2009 - Q4			2010 - Q1			2010 - Q2			2010 - Q3			2010 - Q4			2011 - Q1
US Made & Sold		1,599,208			1,670,992			1,666,840			1,722,965			1,747,662			1,661,465
US Made & ex-US Sold		1,675,718			1,512,620			1,081,147			1,063,551			1,284,652			1,513,340
ex-US Made & Sold		352,659			741,083			1,137,407			1,105,556			1,091,287			969,735
Total		3,627,585			3,924,694			3,885,394			3,892,072			4,123,601			4,144,540
US Made & Sold		44	%		43	%		43	%		44	%		42	%		40	%
US Made & ex-US Sold		46	%		39	%		28	%		27	%		31	%		37	%
ex-US Made & Sold		10	%		19	%		29	%		28	%		26	%		23	%

* As reported to PDL by its licensees

PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2 - March 7, 2011

Attached files

PDL BIOPHARMA, INC. Reports